EXOZ

In September 2026, eXoZymes announced Curia as its commercial-scale manufacturing partner for the NCT program, with production expected to begin in Q4 2026 and scale up in 2027. In August 2026, the company reported its Second Quarter 2026 results, highlighting a 10-fold productivity increase for its NCT process, exceeding commercial targets by producing 67% more NCT per liter and reducing reaction time by over 80%. The company also strengthened its cash position to $5.65 million with $6.59 million in new financing, supporting operations through 2026. In June 2026, eXoZymes was awarded an approximately $2 million Phase IIB Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to advance preclinical development of novel cannabinoid analogs. In May 2026, the company graduated from the Shell GameChanger™ Accelerator Powered by NLR (GCxN) Program, and an investor presentation emphasized a capital-light business model focused on nutraceuticals, pharmaceuticals, cannabinoids, and natural products through spin-outs, joint ventures, and licensing. In April 2026, eXoZymes' CCO, Damien Perriman, discussed the NCTx strategy and commercial path for cell-free biomanufacturing on the Grow Everything Podcast.